In recent years, with the rising prevalence of chronic and infectious diseases, the demand for real-time detection in clinical diagnostics and the need for highly sensitive, portable, enhanced accuracy, rapid immunoassay methods are also increasing. The combination of microfluidic and immunoassay is addressing many challenges faced by the traditional immunoassays during the research & clinical diagnosis. Microfluidic immunoassay is the miniaturization of the laboratory on the chip as it does not require the need of sample preparation steps, benchtop instruments, and trained professionals. The portability of the microfluidic immunoassay is increasing the accessibility of technology in low-resource settings.
Multiplexed Panel Detection is Expected to Gain Traction in the Market
A major trend in the microfluidic immunoassay market is multiplexed panel detection. In many cases, a single molecular event is inadequate to indicate the pathophysiology of diseases such as cancer. Furthermore, using any single molecular event as a biomarker for the early detection of malignancy may not comprehensively identify most individuals with that disease. Therefore, there is a growing need to develop multianalyte-based tests.
The adoption of multiplexed diagnostic testing has increased due to its benefits, such as reduced reagent consumption, multiple analyte detection, improved sensitivity, and shorter reaction time. Microfluidic technology allows fine spatial control in immobilizing proteins and biomolecules within microchannels, allowing for the use of multiplexing and multiparameter assays. Therefore, microfluidic detection of multiple analytes in a single test has become a growing trend.
Many companies are developing multiple-analyte tests to expand their LOC portfolios. POC-based multi-analyte testing for infectious microorganisms could be useful in diagnosing diseases and initiating treatment, as getting results for a laboratory culture-based analysis would be time-consuming, and a single parametric test may not provide accurate diagnosis. Delays in this process may lead to septic shock and death of the patient.
Microfluidic Immunoassay in Cardiology Application
Cardiology deals with the diseases and disorders associated with the heart. The rate of people suffering from heart disease has been increasing in recent years, accounting for 17.1% of deaths in the U.S. Microfluidic immunoassay offers a technologically advanced alternative to the traditional immunoassay for the detection of cardiac diseases in low resource setting, as well as provide rapid test results in case of emergency. Microfluidic cartridges detect the biomarkers released in the blood after injury to the heart muscles. These biomarkers are used as a measure to diagnose cardiovascular disease.
The key market players, including Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Micropoint Biotechnologies Co., Ltd. (China), and QuidelOrtho Corporation (U.S.) are providing the microfluidic cartridges for the assessment of various cardiac biomarkers such as Troponin, creatine kinase (CK-MB), D-Dimer, CRP, and myoglobin.
With the recent research & development in the microfluidic immunoassay market, the focus on introducing multiplexed microfluidic immunoassay is increasing to detect the various cardiac conditions in a single cartridge with a limited amount of sample and in less time. The multiplexed microfluidic panel is also used by the researchers to understand the disease mechanism.
Insights from Microfluidic Immunoassay Market Analysis
Recent insights from Meticulous Research® provide valuable perspectives on the future trajectory of the Microfluidic Immunoassay Market. Projections suggest a potential worth of $1.47 billion by 2030, driven by a remarkable Compound Annual Growth Rate (CAGR) of 7.4% from 2023 to 2030. The recent focus on research & development of microfluidic immunoassay is driving innovation, advancing research & development, and improving patient outcomes. Moreover, significant trends are emerging due to the ongoing evolution of the microfluidic immunoassay market, such as miniaturization and automation of assays, multiplexed detection, portability of the detection systems and microfluidic cartridges, and advancements in fabrication technologies.
As the global landscape takes shape, the North American region is expected to hold a substantial market share in 2023. Notably, influential industry players, including Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), and QuidelOrtho Corporation (U.S.), have established a broad presence across various regions, leading to the widespread adoption of their products. In essence, this comprehensive overview from Meticulous Research serves as a gateway into the microfluidic immunoassay market.
The microfluidic immunoassay market is underway development and is expected to gain traction over the coming years. The market is driven by factors such as the increasing use of microfluidic immunoassays in drug discovery & development and biomarker detection, the advantages of lab-on-chip immunoassays over conventional immunoassays, pharmaceutical & biotechnology companies’ increasing focus on research & development, and the miniaturization of biological and chemical assays. Moreover, the increasing demand for point-of-care diagnostics and recent advancements in microfluidic immunoassay technology are expected to generate market growth opportunities.
Access Full Report Here @ https://www.meticulousresearch.com/product/microfluidic-immunoassay-market-5034